Dicerna Finds RNAi-Savvy Partner in Kyowa for Cancer Drug Program | GenomeWeb

By Doug Macron

Dicerna Pharmaceuticals this week announced that it has signed a deal with Japanese pharmaceutical giant Kyowa Hakko Kirin to develop an RNAi-based cancer drug.

Having consummated the deal in December, Dicerna met its longstanding goal of forging at least one industry partnerships in 2009. At the same time, the company has found in Kyowa a big pharma ally with experience in the RNAi therapeutics field.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.